A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN

Trial Profile

A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Pexidartinib (Primary)
  • Indications Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ENLIVEN
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 07 Nov 2017 Planned End Date changed from 1 Mar 2018 to 1 Oct 2018.
    • 07 Nov 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2018.
    • 31 Oct 2017 Primary endpoint (Percentage of participants achieving complete or partial response) has been met according to a Daiichi Sankyo Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top